Hui Liew1,2, Matthew A Roberts3,4, Alun Pope4, Lawrence P McMahon3,4. 1. Department of Renal Medicine, Eastern Health, 3128, Box Hill, Victoria, Australia. hui.liew@easternhealth.org.au. 2. Eastern Health Clinical School, Monash University, 3128, Box Hill, Victoria, Australia. hui.liew@easternhealth.org.au. 3. Department of Renal Medicine, Eastern Health, 3128, Box Hill, Victoria, Australia. 4. Eastern Health Clinical School, Monash University, 3128, Box Hill, Victoria, Australia.
Abstract
BACKGROUND: Damage to the endothelial glycocalyx is an early indicator of vascular damage and a potential marker of endothelial dysfunction. This study aimed to assess the relationship between markers of glycocalyx damage, endothelial dysfunction, and uraemic toxins in patients with chronic kidney disease. METHODS: Healthy controls, CKD patients, dialysis patients, and kidney transplant recipients had biochemical markers of glycocalyx damage (syndecan-1 and hyaluronan), endothelial dysfunction (von Willebrand factor; vWF and vascular cell adhesion molecule; VCAM-1), and uraemic toxins (indoxyl sulphate and p-cresyl sulphate) measured. In addition, Sidestream Darkfield imaging was performed using the novel GlycoCheck™ device to measure glycocalyx width by the perfused boundary region (PBR) in the sublingual microcirculation. RESULTS: Serum markers of glycocalyx damage were highest in the dialysis group (n = 33), followed by CKD patients (n = 32) and kidney transplant recipients (n = 30) compared to controls (n = 30): hyaluronan: 137 (16-1414), 79 (11-257), 57 (14-218) and 23 (8-116) ng/mL, respectively, p < 0.0001; syndecan-1: 81 (40-529), 46 (21-134), 39 (23-72), and 30 (12-138) ng/mL, respectively, p < 0.0001. Markers of endothelial dysfunction followed a similar pattern. No difference in the width of the PBR was detected between these groups (2.01 ± 0.35, 2.07 ± 0.27, 2.06 ± 0.28, and 2.05 ± 0.3 µm, respectively, p = 0.89). Glycocalyx damage correlated with markers of endothelial dysfunction (log-hyaluronan and log-VCAM-1: r = 0.64, p < 0.001) and levels of uraemic toxins (log-hyaluronan and log-indoxyl sulphate: r = 0.48, p < 0.001). CONCLUSIONS: Levels of biochemical markers of glycocalyx and endothelial cell damage are highest in patients receiving dialysis. Glycocalyx and endothelial damage markers correlated with each other, and with uraemic toxins. Although we could not demonstrate a change in PBR, the biochemical markers suggest that glycocalyx damage is most marked in patients with higher levels of uraemic toxins.
BACKGROUND: Damage to the endothelial glycocalyx is an early indicator of vascular damage and a potential marker of endothelial dysfunction. This study aimed to assess the relationship between markers of glycocalyx damage, endothelial dysfunction, and uraemic toxins in patients with chronic kidney disease. METHODS: Healthy controls, CKD patients, dialysis patients, and kidney transplant recipients had biochemical markers of glycocalyx damage (syndecan-1 and hyaluronan), endothelial dysfunction (von Willebrand factor; vWF and vascular cell adhesion molecule; VCAM-1), and uraemic toxins (indoxyl sulphate and p-cresyl sulphate) measured. In addition, Sidestream Darkfield imaging was performed using the novel GlycoCheck™ device to measure glycocalyx width by the perfused boundary region (PBR) in the sublingual microcirculation. RESULTS: Serum markers of glycocalyx damage were highest in the dialysis group (n = 33), followed by CKD patients (n = 32) and kidney transplant recipients (n = 30) compared to controls (n = 30): hyaluronan: 137 (16-1414), 79 (11-257), 57 (14-218) and 23 (8-116) ng/mL, respectively, p < 0.0001; syndecan-1: 81 (40-529), 46 (21-134), 39 (23-72), and 30 (12-138) ng/mL, respectively, p < 0.0001. Markers of endothelial dysfunction followed a similar pattern. No difference in the width of the PBR was detected between these groups (2.01 ± 0.35, 2.07 ± 0.27, 2.06 ± 0.28, and 2.05 ± 0.3 µm, respectively, p = 0.89). Glycocalyx damage correlated with markers of endothelial dysfunction (log-hyaluronan and log-VCAM-1: r = 0.64, p < 0.001) and levels of uraemic toxins (log-hyaluronan and log-indoxyl sulphate: r = 0.48, p < 0.001). CONCLUSIONS: Levels of biochemical markers of glycocalyx and endothelial cell damage are highest in patients receiving dialysis. Glycocalyx and endothelial damage markers correlated with each other, and with uraemic toxins. Although we could not demonstrate a change in PBR, the biochemical markers suggest that glycocalyx damage is most marked in patients with higher levels of uraemic toxins.
Authors: Martijn J C Dane; Meriem Khairoun; Dae Hyun Lee; Bernard M van den Berg; Bart J M Eskens; Margien G S Boels; Jurgen W G E van Teeffelen; Angelique L W M M Rops; Johan van der Vlag; Anton Jan van Zonneveld; Marlies E J Reinders; Hans Vink; Ton J Rabelink Journal: Clin J Am Soc Nephrol Date: 2014-01-23 Impact factor: 8.237
Authors: Björn K I Meijers; Soetkin Van Kerckhoven; Kristin Verbeke; Wim Dehaen; Yves Vanrenterghem; Marc F Hoylaerts; Pieter Evenepoel Journal: Am J Kidney Dis Date: 2009-07-17 Impact factor: 8.860
Authors: Anurag Singh; Simon C Satchell; Chris R Neal; Edward A McKenzie; John E Tooke; Peter W Mathieson Journal: J Am Soc Nephrol Date: 2007-10-17 Impact factor: 10.121
Authors: Anurag Singh; Raina D Ramnath; Rebecca R Foster; Emma C Wylie; Vincent Fridén; Ishita Dasgupta; Borje Haraldsson; Gavin I Welsh; Peter W Mathieson; Simon C Satchell Journal: PLoS One Date: 2013-02-14 Impact factor: 3.240
Authors: Dae Hyun Lee; Martijn J C Dane; Bernard M van den Berg; Margien G S Boels; Jurgen W van Teeffelen; Renée de Mutsert; Martin den Heijer; Frits R Rosendaal; Johan van der Vlag; Anton Jan van Zonneveld; Hans Vink; Ton J Rabelink Journal: PLoS One Date: 2014-05-09 Impact factor: 3.240
Authors: Margaret A Bush; Salvatore M Florence; Tsin W Yeo; Ayam R Kalingonji; Youwei Chen; Donald L Granger; Matthew P Rubach; Nicholas M Anstey; Esther D Mwaikambo; Joe Brice Weinberg Journal: FASEB J Date: 2021-09 Impact factor: 5.834
Authors: Edmund Y M Chung; Katie Trinh; Jennifer Li; Sebastian Hayden Hahn; Zoltan H Endre; Natasha M Rogers; Stephen I Alexander Journal: Front Cardiovasc Med Date: 2022-05-20
Authors: Axel Muendlein; Eva Maria Brandtner; Andreas Leiherer; Kathrin Geiger; Christine Heinzle; Stella Gaenger; Peter Fraunberger; Dominik Haider; Christoph H Saely; Heinz Drexel Journal: Sci Rep Date: 2022-06-17 Impact factor: 4.996
Authors: Alexander Hof; Simon Geißen; Kezia Singgih; Martin Mollenhauer; Holger Winkels; Thomas Benzing; Stephan Baldus; Friedrich Felix Hoyer Journal: Basic Res Cardiol Date: 2022-07-27 Impact factor: 12.416